Measurable residual disease (MRD) can predict relapse in patients with advanced myelodysplastic neoplasms (MDS) or acute myeloid leukemia
Low- and intermediate-risk myelodysplastic syndromes myelodysplastic syndromes:
The COMMANDS trial established luspatercept as a first-line treatment for anemia anemia:
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious co
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with MDS. The group is hosted by AAMDSIF and will be monitored to ensure the privacy and safety of our participants.
Abstract NRAS and KRAS mutations, commonly identified alongside ancestral co-mutations, are generally regarded as pathogenic in adults presenting with monocytosis and/or cytopenia(s). However, their significance in isolation is not well defined. We studied a multi-institutional…
Abstract Improved ex vivo expansion of human haematopoietic stem cells (HSCs) would considerably advance transplantation and genome-engineered therapies, yet existing culture methods still allow substantial HSC loss. Here we show that this attrition is driven largely by…
This 30-minute webinar reviews the range of opportunities for health care providers to incorporate quality of life considerations with bone marrow failure patients and their caregivers. Assessing resources needed for patients and communicating with the entire health care team…
